{"slug":"uk","tag":"uk","variants":["uk"],"description":"No description yet","count":16,"kinds":{"person":10,"term":6},"related":[{"slug":"law","tag":"law","shared":6},{"slug":"surgery","tag":"surgery","shared":2},{"slug":"bispecific","tag":"bispecific","shared":1},{"slug":"cll","tag":"cll","shared":1},{"slug":"de-escalation","tag":"de-escalation","shared":1},{"slug":"early-detection","tag":"early-detection","shared":1},{"slug":"esophageal","tag":"esophageal","shared":1},{"slug":"genomics","tag":"genomics","shared":1},{"slug":"head-and-neck","tag":"head-and-neck","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1},{"slug":"jak-inhibitor","tag":"jak-inhibitor","shared":1},{"slug":"maintenance","tag":"maintenance","shared":1}],"records":[{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/","tldr":"Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer."},{"id":"paul-nathan","kind":"person","name":"Paul Nathan","route":"/people/paul-nathan/","tldr":"Led the tebentafusp trial, the first treatment ever to extend survival in metastatic uveal melanoma."},{"id":"hisham-mehanna","kind":"person","name":"Hisham Mehanna","route":"/people/hisham-mehanna/","tldr":"Surgeon who led De-ESCALaTE and PET-NECK, two trials that changed how HPV-positive throat cancer is treated and followed up."},{"id":"martyn-caplin","kind":"person","name":"Martyn E. Caplin","route":"/people/martyn-caplin/","tldr":"Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs."},{"id":"dean-fennell","kind":"person","name":"Dean A. Fennell","route":"/people/dean-fennell/","tldr":"Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not."},{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/","tldr":"Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since."},{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","route":"/people/peter-hillmen/","tldr":"Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL."},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/","tldr":"Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant."},{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","route":"/people/serena-nik-zainal/","tldr":"Deciphered the mutational signatures written in cancer genomes and turned them into clinical tests like HRDetect."},{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","route":"/people/rebecca-fitzgerald/","tldr":"Invented the Cytosponge, a swallowable sponge-on-a-string that finds Barrett's oesophagus without endoscopy."},{"id":"ilap","kind":"term","name":"ILAP (Innovative Licensing and Access Pathway)","route":"/terms/ilap/","tldr":"The UK's post-Brexit scheme, launched in 2021 and refreshed in 2025, that brings the medicines regulator, NICE and the NHS together early in a drug's development so that licensing and the decision to pay for it can happen close together."},{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/","tldr":"An NHS England fund that pays for promising cancer drugs while more evidence is collected, born in 2010 as a political fix for drugs NICE had refused and rebuilt in 2016 into a time-limited managed access scheme with a fixed budget."},{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/","tldr":"The rulebook NICE uses to decide whether the NHS in England should pay for a medicine: a cost per quality-adjusted life year usually between 20,000 and 30,000 pounds, with extra weight since 2022 for severe diseases in place of the old bonus for end-of-life cancer drugs."},{"id":"innovative-medicines-fund","kind":"term","name":"Innovative Medicines Fund (England)","route":"/terms/innovative-medicines-fund/","tldr":"A fund launched in 2022 that does for non-cancer medicines what the Cancer Drugs Fund does for cancer: pays for a promising but uncertain drug for a limited period while evidence is gathered, with the same budget of 340 million pounds."},{"id":"medicines-medical-devices-act-2021","kind":"term","name":"Medicines and Medical Devices Act 2021","route":"/terms/medicines-medical-devices-act-2021/","tldr":"The 2021 UK law, passed after Brexit, that gives ministers power to rewrite the rules for licensing medicines, running trials and regulating devices without new primary legislation, and that created a patient safety commissioner."},{"id":"uk-data-protection-act","kind":"term","name":"UK Data Protection Act 2018 and health data law","route":"/terms/uk-data-protection-act/","tldr":"The UK's data law, which keeps the EU's GDPR in domestic form and adds NHS-specific rules, so that cancer registries and research can use patient records under a public-interest basis, patients can opt out of secondary uses, and a 2025 Act loosened the consent rules for scientific research."}]}